Previous 10 | Next 10 |
XOMA (NASDAQ: XOMA ): Q4 GAAP EPS of -$0.49 misses by $0.21 . More news on: XOMA Corporation, Earnings news and commentary, Healthcare stocks news, , Read more ...
Added more than 20 new partner-funded programs in 2019 with potential for milestone and royalty payments Received $15.8 million from partners during the year Current cash balance sufficient to fund operations for multiple years EMERYVILLE, Calif., March 10, 2020 (GLOBE N...
XOMA ( XOMA -7% ) will collaborate with Zydus Cadila to develop an immuno-oncology drug candidate the combines the latter's IL-2 with XOMA's anti-IL-2 monoclonal antibody. More news on: XOMA Corporation, Healthcare stocks news, Stocks on the move, Read more ...
AHMEDABAD, India and EMERYVILLE, Calif., March 09, 2020 (GLOBE NEWSWIRE) -- Zydus Cadila, an innovation-driven global pharmaceutical company, and XOMA Corporation (Nasdaq: XOMA) today announced they have entered into a licensing agreement to advance an IL-2-based immuno-oncology (IO) drug c...
A Little About Me I can remember when I was young and healthy and had no cancer issues or extended hospital stays and no serious surgeries! I was an optimist about everything, including the stock market - especially when it came to dividend growth investing. Invest for the long term, ge...
EMERYVILLE, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present an update about the Company’s business at the Cowen and Company 40 th Annual Health Care Conference in Boston, Massachusetts. ...
Written by Danny Cohen and Scott Matusow We have identified Five Prime Therapeutics ( FPRX ) as a potential turn-around story with upcoming pivotal data, an activist biotech fund with nearly 22% ownership, and important business decisions this year than can make this company a very l...
EMERYVILLE, Calif., Dec. 20, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced the closing of its previously announced rights offering (the “Rights Offering”). At the closing, XOMA sold and issu...
EMERYVILLE, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- As part of its R&D Day on December 5, 2019, Novartis highlighted the progress that has been made on iscalimab (CFZ533), a product candidate, for which XOMA (NASDAQ: XOMA) has the potential to earn royalties that are tiered from a mid...
EMERYVILLE, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has commenced the previously announced rights offering to raise gross proceeds of approximately $22 million (the “Rights...
News, Short Squeeze, Breakout and More Instantly...
2024-07-05 16:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
EMERYVILLE, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has received an $8.1 million milestone payment from Viracta Therapeutics, Inc., related to Day One Biopharmaceuticals’ recent sale of its Priority Revie...
2024-06-04 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...